Table 1.
Characteristics of the patients in the study.
| miR122_H groupc (n = 294) | miR122_L groupc (n = 294) | P value | |
|---|---|---|---|
| Baseline characteristics | |||
| Male (n, %) | 254 (86.4) | 245 (83.3) | 0.300 |
| Age (yrs, mean ± SD)a | 54.9 ± 12.7 | 55.4 ± 13.8 | 0.646 |
| HBeAg positive (n, %) | 59 (20.1) | 68 (23.1) | 0.367 |
| HBV-DNA positive (n, %)a,b | 73 (24.8) | 77 (26.2) | 0.705 |
| Serum ALB (g/L, mean ± SD)a | 32.9 ± 2.3 | 33.0 ± 2.4 | 0.570 |
| Serum TBIL (μmol/L, mean ± SD)a | 14.2 ± 4.6 | 13.7 ± 5.0 | 0.219 |
| Serum AFP (ng/mL, mean ± SD)a | 302.2 ± 155.3 | 338.4 ± 152.0 | 0.004 |
|
| |||
| ECOG score (n, %) a | |||
| 0 points | 119 (40.5) | 135 (45.9) | 0.183 |
| 1 point | 175 (59.5) | 159 (54.1) | |
|
| |||
| Maximum diameter of tumor (n, %) | |||
| ＜5 cm | 136 (46.3) | 115 (39.1) | 0.197 |
| 5∼10 cm | 146 (49.7) | 154 (52.4) | 0.062 |
| ＞10 cm | 12 (4.1) | 25 (8.5) | |
|
| |||
| Number of tumors (n, %) | |||
| Single | 228 (77.6) | 202 (68.7) | 0.016 |
| Multiple | 66 (22.4) | 92 (31.3) | |
|
| |||
| Extent of tumor (n, %) | |||
| Unilateral | 263 (89.5) | 244 (83.0) | 0.023 |
| Bilateral | 31 (10.5) | 50 (17.0) | |
|
| |||
| Portal vein invasion (n, %) | |||
| Absent | 5 (1.7) | 6 (2.0) | 0.666 |
| Unilateral | 191 (65.0) | 176 (59.9) | 0.214 |
| Bilateral or main | 98 (33.3) | 112 (38.1) | |
|
| |||
| Hepatic vein invasion (n, %) | |||
| Absent | 273 (92.9) | 266 (90.5) | 0.296 |
| Present | 21 (7.1) | 28 (9.5) | |
|
| |||
| SOR treatment | |||
| Duration of SOR (week, mean ± SD)a | 16.7 ± 4.1 | 16.3 ± 4.0 | 0.294 |
| Overall adverse events (n, %) | 273 (92.9) | 281 (95.6) | 0.158 |
| Serious adverse events (n, %) | 6 (2.0) | 8 (2.7) | 0.589 |
aSD: standard deviation; HBV: hepatitis B virus; ALB: albumin; TBIL: total bilirubin; AFP: α-fetoprotein; ECOG: eastern cooperative oncology group; SOR: sorafenib. bPositive HBV-DNA was defined as HBV-DNA ≥ 103 copies/ml. cThe patients were divided into the miR122_H group and the miR122_L group according to the median of serum miRNA-122 concentration.